-
Internal Medicine (Tokyo, Japan) 2012We report two cases of membranoproliferative glomerulonephritis, involved in Castleman's disease of hyaline vascular variant and mixed variant, respectively. The... (Review)
Review
We report two cases of membranoproliferative glomerulonephritis, involved in Castleman's disease of hyaline vascular variant and mixed variant, respectively. The diagnoses were confirmed by cervical lymph node and renal biopsy. Both cases were sensitive to chemotherapy with cyclophosphamide, vindesine and prednisone (COP). With the experience from treating case 1, which was misdiagnosed 9 years previously, we followed a more vigilant approach toward case 2 and achieved a more timely diagnosis. Finally, we reviewed pertinent literature of diagnosis and therapy to facilitate an early diagnosis of rare cases in the future.
Topics: Adult; Castleman Disease; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Humans; Hyalin; Male; Middle Aged; Prednisone; Vindesine
PubMed: 22728487
DOI: 10.2169/internalmedicine.51.6298 -
British Journal of Cancer May 2001In order to clarify the role of mitomycin (MMC) in the treatment of NSCLC, we performed a systematic review of the literature and qualitatively assessed the selected... (Meta-Analysis)
Meta-Analysis
In order to clarify the role of mitomycin (MMC) in the treatment of NSCLC, we performed a systematic review of the literature and qualitatively assessed the selected studies using the ELCWP and Chalmers scales. 5 trials (202 patients) assessed the activity of MMC as single-agent chemotherapy in NSCLC. The overall response rate was 25% (95% Cl 19-31). In 10 randomized phase III trials (1769 patients), we studied the role of MMC in combination therapy. A meta-analysis, based on the available published data, failed to show any survival advantage of the MMC containing regimens (hazard ratio = 0.95; 95% Cl 0.83-1.10). Finally, 4 eligible trials (139 patients) assessed the activity of MMC regimens as salvage therapy, 3 in combination with vindesine and one with cisplatin and vinblastine. The overall response rate for the MMC-vindesine regimen was 10.5% (95% Cl 1.7-19.4). In conclusion, MMC is an active drug for NSCLC but does not improve survival when combined with other active drugs, particularly cisplatin. Its use for salvage therapy appears to be associated with marginal activity only.
Topics: Antibiotics, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Mitomycin; Salvage Therapy; Survival Analysis
PubMed: 11336463
DOI: 10.1054/bjoc.2001.1742